Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
A Phase 2b, Open-label Study to Evaluate the Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adult Participants Followed by a Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Immunogenicity and Safety of Hecolin® in Children
Sponsor: Bill and Melinda Gates Foundation
A PHASE2 clinical study on Hepatitis E Virus Infection, this trial is actively recruiting participants. The trial is conducted by Bill and Melinda Gates Foundation and has accumulated 4 data snapshots since 2024. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
4 versions recorded-
May 2025 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — May 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bill and Melinda Gates Foundation
- International Vaccine Institute
- Xiamen Innovax Biotech Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .